SEC.gov | SEC Charges Cassava Sciences, Two Former Executives …
WEB3 days ago · The SEC’s related civil complaint alleges that Cassava and Burns misled investors with claims that the Phase 2 trial was conducted in blinded conditions, even though Wang had been unblinded. The SEC’s complaint further alleges that Cassava misled investors by announcing that the company’s therapeutic significantly improved patient cognition.
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial …
WEB1 day ago · Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC ...
Cassava Sciences shares fall after SEC charges for misleading …
WEB2 days ago · The SEC said Cassava will pay $40 million to settle the civil charges, while Remi Barbier, the company's founder and former CEO, and Lindsay Burns, its former senior vice president of neuroscience ...
Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC ...
WEB1 day ago · Cassava Sciences (SAVA) shares dropped more than 11% after the company agreed to a $40 million settlement with the Securities and Exchange Commission (SEC) over charges that it manipulated ...
Cassava Sciences Resolves SEC Investigation
WEB3 days ago · Cassava, without admitting or denying the SEC’s allegations, agreed to pay a monetary penalty of $40 million. The Company cooperated fully with the SEC’s investigation and has implemented remedial measures. ... Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions ...
Cassava Sciences, Inc., Remi Barbier, and Lindsay Burns - SEC.gov
WEB3 days ago · The SEC’s complaint, filed in the U.S. District Court for the Western District of Texas, charges Cassava with violating Section 17(a)(2) and (3) of the Securities Act of 1933 and Section 13(a) of the Securities Exchange Act of 1934, and Rules 12b-20, 13a-1, 13a-11, and 13a-13 thereunder.
Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims
WEB1 day ago · Drugmaker Cassava Sciences Inc. and two former executives agreed to pay more than $40 million to resolve US Securities and Exchange Commission claims they misled the public about the success of an Alzheimer’s drug trial.. Cassava published results in 2020 based on hand-selected data that showed patients’ memories improved, though the full data showed no measurable progress, the SEC said in ...
SEC Charges Cassava Sciences, Former Executives for
WEB3 days ago · Cassava, Barbier, and Burns also agreed to pay civil penalties of $40 million, $175,000, and $85,000, respectively, the SEC said. The two former executives also agreed to be subject to officer-and ...
Cassava Sciences and former execs agree to SEC fines | STAT
WEB2 days ago · Cassava was charged Thursday by the SEC with making misleading claims in 2020 about trials for its Alzheimer's drug, and agreed to pay fines. ... The news comes on the same day that the SEC filed ...
Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims
WEB2 days ago · September 26, 2024 at 7:11 PM EDT. Save. Drugmaker Cassava Sciences Inc.and two former executives agreed to pay more than $40 million to resolve US Securities and Exchange Commission claims they ...
- Some results have been removed
Skip to content